  | Today's Top Story |  |  | | - ImmunoGen and Lilly unite to develop cancer treatments
ImmunoGen and Eli Lilly and Co. agreed to jointly develop antibody-based cancer drugs in a deal worth at least $20 million. The agreement gives Lilly exclusive licensing rights to some of ImmunoGen's cancer drugs in exchange for a $200 million milestone fee for each drug licensed as well as royalties on any product developed through the partnership. Maytansinoid targeted antibody payload technology developed by ImmunoGen delivers drugs straight to cancer cells. The Wall Street Journal/Dow Jones Newswires (12/20)        | Earn 2X rewards points on advertising costs with The New Business Gold Rewards Card from American Express OPEN. Designed to earn Membership Rewards® points faster:
• 3X points on airfare
• 2X points on advertising, gas, shipping
• 1X points on everything else
LEARN MORE AND APPLY |
  - Scientists keep cancer cells alive in the lab
Scientists at Georgetown University kept lung, breast, prostate and colon cancers alive in a laboratory for up to two years using a stem cell research technique that combines fibroblast feeder cells and a Rho kinase inhibitor to allow reproduction, according to a report in the American Journal of Pathology. Researchers hope the advance will allow lab testing of therapies on a person's own tumors. Yahoo!/Agence France-Presse (12/19) - Breast cancer and heart disease linked, mice study finds
A genetic predisposition to breast cancer may be linked to an increased risk of heart attacks and a sensitivity to a common chemotherapy agent, according Canadian researchers. Mice without BRCA1, the gene that predisposes women to breast cancer, had worse heart damage during heart attacks, were highly likely to die from heart attacks, and had an increased risk for heart failure after doxorubicin chemotherapy than those without the gene. The Gazette (Montreal)/Postmedia News (tiered subscription model) (12/20)  | Let’s Go Design: Episode #7
Before moving into the last stage of production, the team calls a last minute “sanity check” on the final design of the hot rod baby buggy. They look at each of the main components to make sure it rides smoothly. Watch them at work at LetsGoDesign.tv |
 - Takeda pays $190 million upfront for Intellikine
Takeda Pharmaceutical agreed to purchase Intellikine for $190 million upfront and an additional $120 million in milestone payments later. The acquisition gives Takeda access to Intellikine's small-molecule cancer drugs that inhibit many variations of the PI3 kinase pathway. INK218 and INK1117 have the potential to become best-in-class compounds among the drug candidates, Takeda said. Xconomy/Boston (12/20)  | Your job as an Exchange administrator isn't easy. You have to respond to lost messages, handle email discovery requirements, and keep everything up and running. Is there an easy way to manage your Exchange environment — and do it under budget? Learn about the challenges faced by three real organizations, and how using the right solution brought them peace of mind. |
 | Drug Development Basic Training | |  | | |  | - Playing the drug development game
Imagine a video game so complex that few players reach the midpoint, let alone the end. ... Taking a short case study on packaging considerations for a multivalent vaccine, Dr. Paul Nelles, vice president of Vetter Development Service, attempts to offer some of the secrets to winning the drug development game. Biotechnology projects are complex and subject to many levels of risk during the early clinical phases but, by seeking answers to the right questions early, biotech companies can add value to a drug product, potentially attracting investors or increasing out-licensing opportunities. And choosing the right partner to play the game with can lead to improved chances of success. Read the full article here. |  | Increase Productivity, Reduce R&D Spending
This webinar presents new concepts to improve productivity in the lab and discusses the challenges of implementing new technologies in the organic synthesis lab, their acceptance by chemists, and how a sustainable increase of productivity can be achieved. Register for the webinar. |
| Food & Agriculture | | | | - USDA deregulates biotech trait for Monsanto soybean
Biotech trait MON 87705 in the Vistive Gold soybean developed by Monsanto has been deregulated by the U.S. Department of Agriculture. The Vistive Gold soybean's oil is high in monounsaturated fatty acid and low in saturated fat content, unlike traditional soybean oils. With the deregulation, seed production and field trials are now allowed within U.S. under stringent guidelines until Vistive Gold gains regulatory approval in export markets. FoodNavigator (12/20) | Industrial & Environmental | | | | | News from BIO | | | | - BIOtechNOW
BIOtechNOW is the first in a number of new products from BIO intended to enhance our communications with the biotech community -- not only with our members, but with other stakeholders as well. This monthly e-newsletter, combined with its website, serves as our flagship in that effort. BIOtechNOW will offer original content that emphasizes the business needs of the industry; highlight BIO's advocacy efforts; and provide a portal to all BIO activities and events. Most importantly, it will spotlight for those outside the industry the value of biotechnology. Sign up for the monthly BIOtechNOW e-newsletter.
| SmartQuote | | | |  | Has fortune dealt you some bad cards. Then let wisdom make you a good gamester."
--Francis Quarles,
British poet  |
| | This SmartBrief was created for jmabs1@gmail.com
| | | Read more at SmartBrief.com | | A powerful website for SmartBrief readers including: | | | | | | | | | | Recent BIO SmartBrief Issues: - Tuesday, December 20, 2011
- Monday, December 19, 2011
- Friday, December 16, 2011
- Thursday, December 15, 2011
- Wednesday, December 14, 2011
| | | Lead Editor: Tom Parks
Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004 | | | | | | © 1999-2011 SmartBrief, Inc.® Legal Information |
|
No comments:
Post a Comment